Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
p85 protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with trastuzumab.
Pavlakis K, Bobos M, Batistatou A, Kotoula V, Eleftheraki AG, Stofas A, Timotheadou E, Pentheroudakis G, Psyrri A, Koutras A, Pectasides D, Papakostas P, Razis E, Christodoulou C, Kalogeras KT, Fountzilas G. Pavlakis K, et al. Pathol Oncol Res. 2015 Apr;21(2):273-82. doi: 10.1007/s12253-014-9818-2. Epub 2014 Aug 8. Pathol Oncol Res. 2015. PMID: 25098276 Free article.
Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.
Kostopoulos I, Arapantoni-Dadioti P, Gogas H, Papadopoulos S, Malamou-Mitsi V, Scopa CD, Markaki S, Karagianni E, Kyriakou V, Margariti A, Kyrkou E, Pavlakis K, Zaramboukas T, Skordalaki A, Bourli A, Markopoulos C, Pectasides D, Dimopoulos MA, Skarlos D, Fountzilas G. Kostopoulos I, et al. Among authors: pavlakis k. Breast Cancer Res Treat. 2006 Apr;96(3):251-61. doi: 10.1007/s10549-005-9062-2. Breast Cancer Res Treat. 2006. PMID: 16538542 Clinical Trial.
Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.
Malamou-Mitsi V, Gogas H, Dafni U, Bourli A, Fillipidis T, Sotiropoulou M, Vlachodimitropoulos D, Papadopoulos S, Tzaida O, Kafiri G, Kyriakou V, Markaki S, Papaspyrou I, Karagianni E, Pavlakis K, Toliou T, Scopa C, Papakostas P, Bafaloukos D, Christodoulou C, Fountzilas G. Malamou-Mitsi V, et al. Among authors: pavlakis k. Ann Oncol. 2006 Oct;17(10):1504-11. doi: 10.1093/annonc/mdl147. Epub 2006 Sep 12. Ann Oncol. 2006. PMID: 16968874 Free article. Clinical Trial.
Expression and prognostic significance of cyclin D3 in ovarian adenocarcinomas.
Levidou G, Korkolopoulou P, Thymara I, Vassilopoulos I, Saetta AA, Gakiopoulou H, Konstantinidou A, Kairi-Vassilatou E, Pavlakis K, Patsouris E. Levidou G, et al. Among authors: pavlakis k. Int J Gynecol Pathol. 2007 Oct;26(4):410-7. doi: 10.1097/pgp.0b013e31804630a7. Int J Gynecol Pathol. 2007. PMID: 17885491
Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II Trial of the Hellenic Cooperative Oncology Group.
Gogas H, Pectasides D, Kostopoulos I, Lianos E, Skarlos D, Papaxoinis G, Bobos M, Kalofonos HP, Petraki K, Pavlakis K, Bafaloukos D, Fountzilas G. Gogas H, et al. Among authors: pavlakis k. Clin Breast Cancer. 2010 Jun;10(3):230-7. doi: 10.3816/CBC.2010.n.031. Clin Breast Cancer. 2010. PMID: 20497922 Clinical Trial.
Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
Razis E, Bobos M, Kotoula V, Eleftheraki AG, Kalofonos HP, Pavlakis K, Papakostas P, Aravantinos G, Rigakos G, Efstratiou I, Petraki K, Bafaloukos D, Kostopoulos I, Pectasides D, Kalogeras KT, Skarlos D, Fountzilas G. Razis E, et al. Among authors: pavlakis k. Breast Cancer Res Treat. 2011 Jul;128(2):447-56. doi: 10.1007/s10549-011-1572-5. Epub 2011 May 19. Breast Cancer Res Treat. 2011. PMID: 21594665 Free article.
88 results